**Pharmaceutical Services Negotiating Committee**

**Funding and Contract Subcommittee Agenda**

**Wednesday 8th September 2021** 

**Zoom virtual meeting commencing at 09:00 am**

**Items are confidential where marked**

**Members:**David Broome, Peter Cattee (Chairman), Jas Heer, Tricia Kennerley, Margaret MacRury, Has Modi, Bharat Patel, Prakash Patel, Adrian Price, Anil Sharma

**In attendance:**Simon Dukes, Mike Dent, Jack Cresswell, Suraj Shah, Rob Thomas

1. Welcome from Chair
2. Apologies for absence
3. Declarations or conflicts of interest
4. Minutes of last meeting **(Confidential Appendix FCS 01/09/21)**and matters arising

**REPORTS**

1. CPCF negotiations
   1. Service pricing (verbal report)
   2. OPD **(Confidential Appendix FCS 02/09/21)**

1. Remuneration
2. C-19 cost claims update (verbal report)

1. Reimbursement
   1. Category M July 2021 **(Confidential Appendix FCS 03/09/21)**
   2. Margin update **(Confidential Appendix FCS 04/09/21)**
   3. Reimbursement reforms **(Confidential Appendix FCS 05/09/21)**
   4. Price concessions update **(Appendix FCS 06/09/21)**
2. General funding update **(Appendix FCS 07/09/21)**
3. Statistics **(Appendix FCS 08/09/21)**
4. Any other business

Appendix FCS 07/09/21

|  |  |
| --- | --- |
| Subject | General funding update |
| Date of meeting | September 2021 |
| Committee/Subcommittee | FunCon |
| Status | Not confidential |
| Overview | General update on various funding issues |
| Proposed action(s) | No action required |
| Author(s) of the paper | PSNC Dispensing & Supply Team |

**General funding update**

The following items are matters of report:

* [Earlier advance payments for all contractors](#advance_payment)
* [End to temporary suspension of signatures on prescription forms and token submission requirements](#signatures)
* [Inclisiran (Leqvio®) added to a new section in the Drug Tariff (Part VIIIC)](#PARTVIIIC)
* [Single Activity Fee to increase to £1.29 from 1st August](#SAF)
* [July 2021 Category M prices announced](#july_cat_m)
* [SSP endorsement errors](#SSP_endorsement)
* [Levothyroxine: new prescribing advice if specific product required by patient](#levothyroxine)
* [EPS scripts now over 95% of total items](#eps_rx)
* [More than three quarters of pharmacy organisations register for RTEC](#rtec)
* [Summary of new payments including claiming deadlines](#payment_table)
* [Update summary of applications submitted to DHSC for re-determination of special container status](#sc)
* [Further additions to the Discount Not Deducted (DND) list](#dnd)
* [Market movements with implications for supply](#supply)
* [Dispensing Controlled drugs webinar](#cd_webinar)
* [Pharmacy factsheets for community pharmacy](#factsheets)

# Earlier advance payments for all contractors

From November 2021, all community pharmacy contractors will have the chance to receive earlier advance payments, following agreement between PSNC and the Department of Health and Social Care (DHSC).  Advance payments will be made approximately**20 days earlier** than the current payment timetable for contractor who make their monthly FP34C submissions through the [**Manage Your Service (MYS) portal**](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dispensing-contractors-information/manage-your-service-mys) by the 5th of the month.

The paper FP34C submission document will only be available until March 2022 (for February 2022 prescriptions) after which MYS will be the only route for all monthly submissions. Contractors who continue to use the paper FP34C submission document (from November 2021 to March 2022) will **NOT** receive any earlier advance payments but instead will receive advance payments in accordance with the current payment timetable i.e on or around the 1st of the month following submission. **Therefore, contractors who use paper FP34Cs for their monthly submissions are strongly encouraged to start using the MYS portal to make their declarations.**

**The final reconciliation payment date remains unchanged** i.e. this will continue to be paid on the 1st working day of the month approximately two months after contractors have submitted the appropriate FP34C form and prescriptions for pricing.

Over **50%** of pharmacy contractors are now using [Manage Your Service (MYS)](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dispensing-contractors-information/manage-your-service-mys)to submit their end-of-month FP34C figures digitally. In June 2021, the NHS Business Services Authority (NHSBSA) confirmed that **over 6,000** contractors used the MYS portal for their end-of-month submissions.

In addition to the notice of the end of PEPS, the changes to the advance payment timetable and submission requirements, the published [Drug Tariff determination for September 2021](https://www.nhsbsa.nhs.uk/pharmacy-earlier-payment-scheme-peps-announcement-dhsc-26-august-2021) also outlines:

* different payment arrangements for late submissions which will also incur administrative charges;
* an extension to the deadlines for submission of FP34C and dispatch of prescription bundle in months where a bank holiday occurs during the first five days of the month;
* contingency arrangements for contractors who are unable to submit FP34C through MYS; and
* requirements for prescriptions issued via Electronic Prescription Service (EPS) and token submission.

Please note that the changes above are not reflected in the published version of the [September 2021 Drug Tariff](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff).

Click [here](https://psnc.org.uk/our-news/early-advance-payments-for-all-contractors-following-an-end-to-peps/) to view the full story. Further details for contractors are outlined in this [PSNC Briefing](https://psnc.org.uk/wp-content/uploads/2021/08/PSNC-Briefing-032.21.-New-payment-arrangements-for-ALL-contractors-following-end-to-Pharmacy-Earlier-Payment-Scheme-PEPS.pdf)

PSNC also plan to hold a webinar for contractors to explain the changes and offer further practical support. Details on the webinar to follow.

End to temporary suspension of signatures on prescription forms and token submission requirements

On 31 August 2021, the temporary suspension of the need for signatures on prescription forms and/or EPS tokens comes to an end, ten months after it was first introduced. This will also mean an end to the temporary suspension of the requirement to submit certain EPS tokens to the NHS Business Services Authority (NHSBSA). As Ministers remain keen for public policy priorities to return to normal, the easing of wider COVID-19 restrictions coupled with the slowing in the number of infections did not support a case for any further extensions to this suspension period.

**From September 2021, patients (or their representatives) will be required to sign the reverse of NHS prescription forms or tokens for all prescriptions presented at the pharmacy on or after 1 September 2021.**In preparation for the end of the temporary suspension period, contractors are advised to make plans to return to capturing of signatures on NHS prescriptions/tokens and review current submission processes to include relevant tokens with monthly bundles from September.

**Contractors should check their current stock levels of tokens and only order additional tokens if required.**Tokens can be ordered from Primary Care Support England (PCSE) by following the token ordering process outlined [here](https://psnc.org.uk/wp-content/uploads/2021/02/EPS-token-ordering-and-escalation-factsheet-.pdf).

For more information on the return to capturing patient signatures on prescription forms and token submission requirements, see our full story [here](https://psnc.org.uk/our-news/end-to-temporary-suspension-of-signatures-on-prescription-forms-and-token-submission-requirements/).

Inclisiran (Leqvio®) added to a new section in the Drug Tariff (Part VIIIC)

**From September 2021, the**[Drug Tariff](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff)**includes a new section, Part VIIIC, which sets out arrangements of payment for products with a nominal price (i.e where the purchase price of the product is significantly lower than its NHS list price).**

Products listed in Part VIIIC are available at nominal prices because of commercial deals in place between the manufacturer or supplier and the NHS England and NHS Improvement (NHSE&I) which allows manufacturers to supply a drug to the NHS at a reduced cost compared to its published NHS list prices as authored in the [NHS Dictionary of Medicines and Devices (dm+d)](https://services.nhsbsa.nhs.uk/dmd-browser/). Part VIIIC outlines the reimbursement price of one product, Inclisiran, under such a commercial arrangement.

For more information on Part VIIIC and Inclisiran see our full story [here](https://psnc.org.uk/our-news/inclisiran-leqvio-added-to-a-new-section-in-the-drug-tariff-part-viiic/).

Single Activity Fee to increase to £1.29 from 1st August

In order to ensure delivery of £1.792bn in fees and allowances in the financial year 2021/22, the value of the Single Activity Fee will increase to £1.29 from 1st August 2021. You can view the August 2021 Drug Tariff now on the [NHSBSA website](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff).

PSNC has agreed the increase based on our analysis of funding delivery and the latest projections for the year. Fee levels are kept under constant review in order to ensure the full delivery of funding agreed under the Community Pharmacy Contractual Framework.

July 2021 Category M prices announced

The Drug Tariff Category M pricelist for July 2021 has been published on the [NHS Business Services Authority (NHSBSA) website](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-part-viii).

The July Category M prices reflect a reduction in margin levels of approximately £34m per quarter. The £15m per quarter uplift that has been in place for the last 3 quarters to mitigate against the impact of Brexit will also be removed from the July Drug Tariff. As such the total quarterly impact on margin will be a £49m reduction, or approximately – 19 pence per item on average. The underlying effect of market price movements in the reference period January – March 2021 will also be reflected in the July Drug Tariff.

PSNC has agreed the adjustments based on our analysis of margin delivery and on current projections for 2020/21. Our objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies will vary depending on dispensing mix.

SSP endorsement errors

Following the [announcement](https://psnc.org.uk/our-news/new-ssp-endorsement-introduced/) of the new Serious Shortage Protocols (SSP) endorsement which was introduced from 1 June 2021, PSNC has been working with NHS Business Services Authority (NHSBSA) to understand if SSP claims are being submitted in accordance with the updated [SSP endorsement guidance](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/serious-shortage-protocols-ssps).

During the month of June 2021, NHSBSA received a number of EPS SSP claim messages (Electronic Reimbursement Endorsement Messages (EREMs)) which did not meet the requirements for a valid SSP claim.  The main reasons for these incorrect/invalid SSP claims were due to:

1. **Incorrect item endorsed**– Incorrect item endorsed was almost always the same as original prescribed item rather than the alternative supplied in accordance with a valid SSP. Majority of the SSP errors were for incorrect item endorsed.
2. **Invalid or incorrect SSP reference number endorsed**– For example SSP 000, SSP (missing reference number), SSP 028 (incorrect number), SSP 05 (two instead of three digits).
3. **SSP claims for prescribed items without an active SSP**– SSP endorsed against items for which an SSP did not exist.
4. **Claims for supplies made in accordance with an expired SSP:**
   * No active SSP in place at the time of supply – ie SSP claimed for items on prescriptions issued after SSP expired
   * Alternative item correctly supplied during the period of SSP validity but Dispense Notification message submitted after the period of SSP validity
   * Alternative item correctly supplied during the period of SSP validity and the Dispense Notification message submitted during the period of SSP validity but the EREM or Claim Notification message submitted after the 3-month claiming window.

NHSBSA is issuing some guidance and support to system suppliers implementing the EPS SSP feature.  Suppliers also have some flexibility as to the extent to which they will support pharmacy team members for example, by asking users to complete any missing or incomplete SSP endorsement information if the required endorsements are not present or not in the specified format.

Note: As reported previously, during the transition period (until end of September dispensing month), NHSBSA will accept either the new ‘SSP’ or existing ‘NCSO’ endorsement for any SSP claims submitted using electronic prescriptions, EPS tokens of FP10 paper prescriptions.

View examples of invalid/incorrectly endorsed SSP claims submitted via EPS [here](https://psnc.org.uk/our-news/contractor-notice-ssp-endorsement-errors-2/).

The following SSPs have been authorised by the Secretary of State to help manage the supply of these products and to try to ensure that fewer patients need to return to their prescriber. **SSPs may be amended or revoked at any time, view up-to-date information on the NHSBSA website**.

**Active SSPs**

|  |  |
| --- | --- |
| **SSP** | **Current expiry date** |
| [SSP05: Fluoxetine 10mg tablets](https://www.nhsbsa.nhs.uk/sites/default/files/2020-03/SSP%20Fluoxetine%2010mg%20tablets%20final%20-%20signed.pdf) | 12 November 21 |

Further information on SSPs can be found on PSNC’s [Live SSPs](https://psnc.org.uk/dispensing-supply/supply-chain/live-ssps/) webpage

Levothyroxine: new prescribing advice if specific product required by patient  
  
The May 2021 [MHRA Drug Safety Update](https://www.gov.uk/drug-safety-update/levothyroxine-new-prescribing-advice-for-patients-who-experience-symptoms-on-switching-between-different-levothyroxine-products) contains new prescribing advice for patients who experience symptoms on switching between levothyroxine products.

The advice for healthcare professional's states that:

* generic prescribing of levothyroxine remains appropriate for the majority of patients
* a small proportion of patients treated with levothyroxine report symptoms, often consistent with thyroid dysfunction, when their levothyroxine tablets are changed to a different product
* if a patient reports persistent symptoms when switching between different levothyroxine products, prescribers should consider consistently prescribing a specific levothyroxine product known to be well tolerated by the patient.
* if symptoms or poor control of thyroid function persist (despite adhering to a specific product), prescribers should consider prescribing an oral solution formulation of levothyroxine

Following this advice, community pharmacy teams may expect to receive requests from patients and/or prescribers for a specific brand name or make of levothyroxine to be supplied against a prescription. If a specific levothyroxine product known to be well tolerated by the patient is required, prescribers must ensure the correct product description is selected using their prescribing systems. In EPS, if a specific brand name or supplier of the product is selected, this will appear in the prescription drug name field.

PSNC is aware that some pharmacy contractors have been left out of pocket because prescribers have free-typed product information (such as brand name or supplier) into the dosage instructions field or notes section of electronic prescriptions, and the pharmacy has not been reimbursed for supplying in accordance with the prescribers instructions.

View the full story with guidance [here](https://psnc.org.uk/our-news/levothyroxine-new-prescribing-advice-if-specific-product-required-by-patient/).

EPS scripts now over 95% of total items

Electronic prescriptions sent via the Electronic Prescription Service (EPS) now represent more than 95% of all prescriptions dispensed by community pharmacies in England.\*

[One-off nomination](https://psnc.org.uk/dispensing-supply/eps/patient-nomination-of-a-dispensing-site/)is now available in many GP practices and other care settings, allowing prescriptions to be sent to an alternative pharmacy without affecting a patient’s existing nominations and avoiding the need for paper prescriptions to be issued by prescribers.

The latest figures show that more than 95% of GP practices are now using [Phase 4 EPS](https://psnc.org.uk/phase4).

\*NHSBSA confirmed the volumes at the latest [pharmacy IT group meeting](https://psnc.org.uk/our-news/it-group-progresses-workstreams-at-its-quarterly-meeting/).

More than three quarters of pharmacy organisations register for RTEC

NHSBSA has reported that more than three quarters of pharmacy organisations have now registered to access Real Time Exemption Checking (RTEC).

[RTEC](https://psnc.org.uk/dispensing-supply/eps/electronic-prescription-service-eps-sitemap/real-time-exemption-checking-rtec/) allows pharmacy teams to digitally check if their patients are eligible for free NHS prescriptions because they hold specific exemptions.

Pharmacies already using RTEC report that it saves staff time and because a patient that is found to be exempt via RTEC does not need to complete an exemption declaration on an EPS token, it reduces the use of paper, decreasing the risk of transmission of infection during the COVID-19 pandemic.

View the full story and information on how to register [here](https://psnc.org.uk/our-news/more-than-three-quarters-of-pharmacy-orgs-register-for-rtec/).

Summary of new payments including claiming deadlines

The Dispensing & Supply team has created a payment timetable and deadline tracker to assist community pharmacy contractors with checking and claiming payments for services including the  [Covid-19 Costs](https://psnc.org.uk/our-news/covid-19-costs-psnc-reaches-deal-with-hm-government/), [Pharmacy Quality Scheme (PQS) 2020/21 Part 2](https://psnc.org.uk/services-commissioning/pharmacy-quality-scheme/pqs-2020-21-part-2/), [C-19 lateral flow device distribution service](https://psnc.org.uk/services-commissioning/advanced-services/c-19-lateral-flow-device-distribution-service/), [Pandemic Delivery Service](https://psnc.org.uk/the-healthcare-landscape/covid19/pandemic-delivery-service/), [GP Community Pharmacist Consultation Service (CPCS)](https://psnc.org.uk/services-commissioning/advanced-services/community-pharmacist-consultation-service/cpcs-gp-referral-pathway/), [Discharge Medicines Service](https://psnc.org.uk/services-commissioning/essential-services/discharge-medicines-service/),  [Covid-19 vaccinations](https://psnc.org.uk/the-healthcare-landscape/covid19/covid-19-vaccinations/) and [Hepatitis C testing service](https://psnc.org.uk/services-commissioning/advanced-services/hep-c/).

The table below outlines payments for different services providing details of any claim deadlines (where applicable), how to claim, timing of payments, payment amounts and how these payments will appear on the Schedule of Payments.

| **Payment type** | **Claim method** **(deadline to claim for payment)** | **Payment due** | **Payment amount** | **How payment will appear on the Schedule of Payments under section of ‘Details of other amounts authorised’** |
| --- | --- | --- | --- | --- |
| **COVID-19 Costs** **(incurred between 1 March 2020 – 31 March 2021 for the delivery of NHS pharmaceutical services)** | [Claim form on NHSBSA website](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dispensing-contractors-information/pharmaceutical-services-provider-assurance/reimbursement-covid-19-costs) – available from 5th July  (deadline to submit claim is **11:59pm on 15th August**) | 1st October | Contractors can claim for the following:  1. Additional staff costs due to COVID-19  2. Costs incurred to make premises COVID-19 secure  3. IT and communication costs to support home working and virtual patient contact; and  4. Notified closures for infection control purposes (maximum 14 days) | Reimbursement will appear as: ‘Reimbursement of Covid-19 costs’ |
| Adjustment will appear as: ‘Reimbursement of Covid-19 costs adj’ |
| Recovery will appear as: ‘Recovery of 20/21 Covid-19 Cash Advance’ |
| **COVID-19 Lateral Flow Device Distribution Service** | MYS  (by the 5th day of the following month) Appropriate payments, will correspond to the weekly reporting cycle, on the same payment date as other payments for NHS Pharmaceutical Services | Monthly – service currently extended until **29th August** | £1.50 + VAT Service fee per transaction | ‘COVID Testing Kit’ |
| **COVID-19 Lateral Flow Device Distribution Service Set-Up Fee** | MYS | One-off payment | £250 + VAT | ‘COVID Test Kit Set up Fee’ |
| **Pandemic Delivery Service (Essential service)\*** | Automatic | Monthly  Self-isolating patients only **(from 1st April 2021 onwards)**as confirmed by NHS Test and Trace (for the 10-day self-isolation period). This service will continue until **23:59 on 30th September** | Table  Description automatically generated | Paid on the same line as ‘Transitional Payment’. It will show as a total figure |
| **Pandemic Delivery Service (Advanced service)\*** | MYS (by the 5th day of the following month) | Monthly – service currently extended until **30th September** for all people notified of the need to self-isolate by NHS Test and Trace (for the 10-day self-isolation period) living in England | £6 (including VAT) per delivery | Payment will be listed as ‘Additional advance payment’ under section titled ‘Summary of Payment Amounts’ |
| **Community Pharmacist Consultation Service (CPCS)** | MYS (by the 5th day of the following month) | Monthly | £14 (no VAT applicable) for each completed referral | ‘CPCS Remuneration Payment’ |
| **Discharge Medicines Service (DMS)** | MYS Note: DMS commenced on 15th February 2021 | Monthly – the first service payment is due on 30th April for any claims submitted in February (after 15th) | Table  Description automatically generated | ‘Discharge Medicine Review Fee’ |
| **COVID-19 vaccinations** | MYS | Monthly (First payments will be made on 1st April) | £12.58 is paid for each vaccination given  Additional £10.00 payment per vaccine for housebound and care home patients. | ‘Covid Vaccine Claim’ |
| **Hepatitis C testing service** | MYS (by the 5th day of the following month after completion of a test) | Monthly in the same payment month as other payments for NHS Pharmaceutical Services | £36 per test performed | ‘Hep C Provision of Testing Service’ |
| **Hepatitis C Point of Care Test (POCT) kit** | MYS (by the 5th day of the following month after completion of a test) | Monthly in the same payment month as other payments for NHS Pharmaceutical Services | Cost of the POCT kit at manufacturer’s list price + VAT | ‘Hep C Test Kit Reimbursement’ |

*\*Excludes distance -selling pharmacies*

Update summary of applications submitted to DHSC for re-determination of special container status

**Special Container applications update:** PSNC have reached out to DHSC to provide us with a response to the **736** outstanding special container applications. PSNC have requested that DHSC outline their position for each individual product.

To help expedite the process PSNC have offered to provide any written confirmation we have from manufacturers where we have permission to do so.

Since August 2019, PSNC’s Dispensing & Supply team has reviewed over **4,000** products against Drug Tariff special container criteria. The three main criteria under which PSNC has focused its attention are drugs that are considered hygroscopic, viscous external preparations and those packaged into containers from which it is not practical to dispense the exact quantity. Of those checked, PSNC has identified and submitted applications for **856** products that appear to meet one or more of the special container criteria but are not annotated as such in the Drug Tariff and/or the dm+d. See our page on ‘[*Notice of changes to special container status of products*’](https://psnc.org.uk/dispensing-supply/dispensing-a-prescription/special-containers/special-containers-notice-of-change-to-product-special-container-status/).

The table below provides latest information on the number of products that have been submitted to DHSC and NHSBSA for further investigation and the status of these applications.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Special container criteria** | **Number of products checked** | **Number of products applied for** | **Number of products currently in discussion with DHSC or under review with NHSBSA** | **Number of products agreed by DHSC as meeting criteria** |
| **Effervescent or hygroscopic\*** | **263** | **221** | **180** | **33** |
| **Viscous external preparations\*** | **891** | **136** | **124** | **12** |
| **Packaged in a container from which it is not practicable to dispense exact quantity\*** | **2,992** | **504** | **432** | **66** |
| **Total** | **4,146** | **861** | **736** | **111** |

*\*Please note some products may have been applied for under more than one criteria*

PSNC has submitted a paper to DHSC setting out its concerns relating to the current processes for determining the special container status of products and included proposals to facilitate more accurate assessment of products against the relevant Drug Tariff criteria.

Further additions to the Discount Not Deducted (DND) list

Over the past 12 months, following contractor feedback and through internal Dispensing & Supply team checks, product applications for DND status have been submitted to the NHSBSA and DHSC for **over 480** products. Of these, **372** products have been agreed to by DHSC and added to the DND list in the Drug Tariff. For a list of all the monthly changes to the DND status of products please see the following page***‘***[*Notice of changes to discount not deducted (DND) status of products*](https://psnc.org.uk/dispensing-supply/endorsement/discount-deduction/notice-of-changes-to-discount-not-deducted-dnd-status-of-products/)*'.*

The team has also started their yearly analysis into finding new DND products and will make periodic applications to NHSBSA and DHSC.

Market movements with implications for supply

The following **19** supply disruption alerts and medicine supply notifications (issued by DHSC between 15 May 2021 and 2 August 2021) were published on the PSNC website by the Dispensing & Supply team to assist pharmacy teams:

| **Date** | **Drug name** |
| --- | --- |
| 02/08/21 | [Glipizide (Minodiab®) 5mg tablets](https://psnc.org.uk/our-news/supply-disruption-alert-glipizide-minodiab-5mg-tablets/) |
| 29/07/21 | [Tinzaparin sodium (10,000 IU/ml) 3,500 units in 0.35 ml and 4,500 units in 0.45 ml pre-filled syringes](https://psnc.org.uk/our-news/supply-disruption-alert-tinzaparin-sodium-10000-iu-ml-3500-units-in-0-35-ml-and-4500-units-in-0-45-ml-pre-filled-syringes/) |
| 28/07/21 | [Clexane® (enoxaparin) pre-filled syringes](https://psnc.org.uk/our-news/medicine-supply-notification-clexane-enoxaparin-pre-filled-syringes/) |
| 28/07/21 | [Trifluoperazine 1mg/5ml syrup (Advanz Pharma) – Update](https://psnc.org.uk/our-news/medicine-supply-notification-trifluoperazine-1mg-5ml-syrup-advanz-pharma/) |
| 21/07/21 | [Nexium® (esomeprazole) 10mg gastro-resistant granules sachets](https://psnc.org.uk/our-news/medicine-supply-notification-nexium-esomeprazole-10mg-gastro-resistant-granules-sachets/) |
| 21/07/21 | [Catapres® (clonidine) 100microgram tablets](https://psnc.org.uk/our-news/medicine-supply-notification-catapres-clonidine-100microgram-tablets/) |
| 21/07/21 | [Locorten Vioform® (flumetasone/clioquinol) 0.02% w/v / 1% w/v ear drops solution](https://psnc.org.uk/our-news/medicine-supply-notification-locorten-vioform-flumetasone-clioquinol-0-02-w-v-1-w-v-ear-drops-solution/) |
| 21/07/21 | [Diamorphine hydrochloride powder for reconstitution and injection 5mg and 10mg ampoules – Update](https://psnc.org.uk/our-news/medicine-supply-notification-diamorphine-hydrochloride-powder-for-reconstitution-and-injection-5mg-and-10mg-ampoules/) |
| 12/07/21 | [Gentisone HC® (Gentamicin 0.3% w/v and Hydrocortisone acetate 1% w/v) Ear Drops](https://psnc.org.uk/our-news/medicine-supply-notification-gentisone-hc-gentamicin-0-3-w-v-and-hydrocortisone-acetate-1-w-v-ear-drops/) |
| 25/06/21 | [Dexamethasone 0.1% (Maxidex) 5ml eye drops](https://psnc.org.uk/our-news/supply-disruption-alert-dexamethasone-0-1-maxidex-5ml-eye-drops/) |
| 24/06/21 | [Champix (Varenicline) 0.5mg and 1mg tablets – Pfizer](https://psnc.org.uk/our-news/supply-disruption-affecting-champix-varenicline-tablets-pfizer/) |
| 17/06/21 | [Kolanticon gel® (2.5mg dicycloverine hydrochloride, 200mg aluminium hydroxide, 100mg light magnesium oxide, 20mg simethicone per 5ml)](https://psnc.org.uk/our-news/medicine-supply-notification-kolanticon-gel-2-5mg-dicycloverine-hydrochloride-200mg-aluminium-hydroxide-100mg-light-magnesium-oxide-20mg-simethicone-per-5ml/) |
| 14/06/21 | [Fluoxetine (Olena) 20mg dispersible sugar free tablets](https://psnc.org.uk/our-news/medicine-supply-notification-fluoxetine-olena-20mg-dispersible-sugar-free-tablets/) |
| 14/06/21 | [Dalacin® (clindamycin) 2% vaginal cream](https://psnc.org.uk/our-news/medicine-supply-notification-dalacin-clindamycin-2-vaginal-cream/) |
| 28/05/21 | [Alliance Calcium Syrup (calcium gluconate 544mg/5ml calcium lactate 276mg/5ml oral solution)](https://psnc.org.uk/our-news/medicine-supply-notification-alliance-calcium-syrup-calcium-gluconate-544mg-5ml-calcium-lactate-276mg-5ml-oral-solution/) |
| 28/05/21 | [Flixotide® (fluticasone propionate) 100 microgram Accuhaler – Update](https://psnc.org.uk/our-news/medicine-supply-notification-flixotide-fluticasone-propionate-100-microgram-accuhaler/) |
| 28/05/21 | [Fluoxetine 30mg capsules (Advanz) – Update](https://psnc.org.uk/our-news/medicine-supply-notification-fluoxetine-30mg-capsules-advanz/) |
| 13/05/21 | [VFEND (Voriconazole) 40mg/ml powder for oral suspension – Updated](https://psnc.org.uk/our-news/medicine-supply-notification-vfend-voriconazole-40mg-ml-powder-for-oral-suspension/) |
| 12/05/21 | [Irbesartan/ hydrochlorothiazide 150mg/12.5mg tablets – Update](https://psnc.org.uk/our-news/medicine-supply-notification-irbesartan-hydrochlorothiazide-150mg-12-5mg-tablets/) |

Dispensing Controlled drugs webinar   
  
PSNC’s Dispensing Controlled Drugs (CDs) webinar for community pharmacy teams is now available to watch on-demand. Of the participants who joined the event last night, **96%** of attendees found it useful, with **90%** saying they would recommend it to others. [Click here to view an on-demand version of the webinar](https://view6.workcast.net/?cpak=6496242485766111&pak=2288538569801742)

Pharmacy factsheets for community pharmacy

The [May 2021 edition of Community Pharmacy News (CPN) magazine](https://psnc.org.uk/our-news/may-cpn-magazine-published/) was the last issue produced by PSNC.

PSNC will continue to produce its daily email updates so that community pharmacists and their teams receive important information and guidance from us in a timely manner. We will also continue to publish the content that appeared in CPN on our website: this will include the Dispensing and Supply Team factsheets and monthly Drug Tariff Watch.

| **CPN Month** | **Factsheet title** |
| --- | --- |
| July-21 | [FOC items factsheet](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=0df9047a7e&e=a14d94e535) |
| May-21 | [Understanding Prescription Returns](https://psnc.org.uk/wp-content/uploads/2021/06/Factsheet-Understanding-Prescription-Returns.pdf) |
| Apr-21 | [Multi-Charge Items](https://psnc.org.uk/wp-content/uploads/2021/05/Dispensing-Factsheet-Multi-charge-Items.pdf) and [How to access your Prescription Item Reports](https://psnc.org.uk/wp-content/uploads/2021/03/Dispensing-Factsheet-How-to-access-your-Prescription-Item-Reports.pdf) |
| Mar-21 | [Expensive Items](https://psnc.org.uk/wp-content/uploads/2021/05/Expensive-items-factsheet.pdf) |
| Feb-21 | [Dispensing prescriptions for Controlled Drugs](https://psnc.org.uk/wp-content/uploads/2021/03/CPN_0221_Dispensing-Factsheet-Dispensing-prescriptions-for-Controlled-Drugs.pdf) |
| Jan-21 | [Disallowed items](https://psnc.org.uk/wp-content/uploads/2021/02/Dispensing-Factsheet-Disallowed-items.pdf) |
| Dec-20 | [Is this item allowed](https://psnc.org.uk/wp-content/uploads/2021/01/Dispensing-Factsheet-Is-this-item-allowed.pdf) |
| Nov-20 | [Dispensing and submission guidance following the suspension of patient signatures on prescriptions](https://psnc.org.uk/wp-content/uploads/2020/11/Appendix1-for-PSNC-Briefing-040.20.pdf) |
| Oct-20 | [Red separator submission](https://psnc.org.uk/wp-content/uploads/2020/11/Red-Separator-Factsheet.pdf) |
| Sep-20 | [Prescription re-check](https://psnc.org.uk/wp-content/uploads/2020/11/Rechecks-Factsheet-002.pdf) |
| Aug-20 | [Exemptions from prescription charges](https://psnc.org.uk/wp-content/uploads/2020/09/Prescription-exemptions-factsheet.pdf) |
| Jul-20 | [New prescriber endorsement ‘FS’ for free supply of sexual health treatment](https://psnc.org.uk/wp-content/uploads/2020/10/FS-endorsement-factsheet.pdf) |
| Jun-20 | [All you need to know about: Special containers and products requiring reconstitution](https://psnc.org.uk/wp-content/uploads/2020/11/Special-containers-factsheet.pdf) |
| May-20 | [C-19 related payments in June/July](https://psnc.org.uk/wp-content/uploads/2020/05/May-2020-CPN.pdf) |
| Apr-20 | [C-19 related payments in April/May](https://psnc.org.uk/wp-content/uploads/2020/04/April-2020-CPN.pdf) |
| Mar-20 | [Dispensing Factsheet: Prescription endorsements](https://psnc.org.uk/wp-content/uploads/2020/11/Prescription-endorsements-factsheet.pdf) |
| Feb-20 | [Dispensing and endorsing FP10MDA instalment forms correctly](https://psnc.org.uk/wp-content/uploads/2020/03/FP10-MDA-Factsheet_CPN_0220.pdf) |
| Jan-20 | [Changes to FP10 NHS Prescription forms and EPS Tokens](https://psnc.org.uk/wp-content/uploads/2020/11/Changes-to-FP10s-factsheet.pdf) |

Appendix FCS 08/09/21

|  |  |
| --- | --- |
| Subject | Statistics |
| Date of meeting | September 2021 |
| Committee/Subcommittee | FunCon |
| Status | Not confidential |
| Overview | Latest statistics for information |
| Proposed action(s) | No action required |
| Author(s) of the paper | PSNC Pharmacy Funding Team |

**Statistics**

The latest rolling 12 month item volume as per **May-21** is **1,027.7m** items.

In the last 24 months the peak was **1,055.7m** items in **Apr-20**.

**Chart, line chart

Description automatically generated**

The **Jul-21** Cat-M list will have an estimated impact of **-23 pence per item** on like-for-like reimbursement

**Chart, line chart

Description automatically generated**

The cumulative total of like-for-like changes since 2019 is currently **+27 pence per item**

**Chart, line chart

Description automatically generated**



**Chart, bar chart

Description automatically generated**

In **20/21 Q4** the average fees per item increased by **+6 pence per item** to **£1.69**.

**Chart, bar chart

Description automatically generated**

**Pharmacy contract numbers**

A waterfall chart of net change in pharmacy numbers per month indicates a cumulative drop of c-533 in the total number of pharmacy contracts since the announcement of the funding cuts.

Chart, waterfall chart

Description automatically generated

A long view of pharmacy contract numbers demonstrates steady growth since the introduction of the new contract in 2005, followed by a reversal from early 2018 onwards.

A screenshot of a computer

Description automatically generated with medium confidence